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Tissue-type plasminogen activator (tPA) is a serine proteinase found not only in the
intravascular space but also in a well-defined sub-set of neurons in the brain. tPA
is rapidly released from neurons after either exposure to hypoxia or hypoglycemia
in vitro, or the induction of cerebral ischemia in vivo. It has been proposed
that tPA has a neurotoxic effect in the ischemic brain. However, recent evidence
indicate that once released into the synaptic cleft tPA activates specific cell signaling
pathways that promote the detection and adaptation to metabolic stress. More
specifically, the non-proteolytic interaction of tPA with N-methyl-D-aspartate receptors
(NMDARs) and a member of the low-density lipoprotein receptor (LDLR) family in
dendritic spines activates the mammalian target of rapamycin (mTOR) pathway that
adapts cellular processes to the availability of energy and metabolic resources. TPA-
induced mTOR activation in neurons leads to hypoxia-inducible factor 1α (HIF-1α)
accumulation, HIF-1α-induced expression and membrane recruitment of the neuronal
transporter of glucose GLUT3, and GLUT3-mediated uptake of glucose. These and
other data discussed in this Review suggest that the postulated neurotoxic effect
of tPA needs to be reconsidered and instead indicate the emergence of a new
paradigm: that tPA is an endogenous neuroprotectant in the central nervous system
(CNS).
Keywords: cerebral ischemia, neurovascular unit (NVU), middle cerebral artery occlusion (MCAo), tissue-type
plasminogen activator (tPA), neuroprotection, excitotoxicity, plasminogen
Introduction
Tissue-type plasminogen activator (tPA) is a serine proteinase of 527 residues. It has an A chain
with a finger, an EGF and two kringle domains, and a B chain with a protease domain. tPA is
secreted as a single chain molecule (sctPA), but cleavage by plasmin at its Arg275-Ile276 peptide
bond generates two-chain tPA (tctPA). sctPA is not a zymogen and in the presence of fibrin is
almost as active as tctPA (Rijken et al., 1982).
Our understanding of tPA’s function in the brain has evolved rapidly. Indeed, although
it was initially believed that endothelial cells (ECs) were the sole source of tPA and that its
unique role was to catalyze the conversion of plasminogen into plasmin in the intravascular
space, today we know that tPA is expressed in the brain parenchyma, where it has several
functions, many of them independent of its ability to catalyze the conversion of plasminogen into
plasmin.
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tPA in the Brain
To better understand tPA’s effect on neuronal survival is pivotal
to consider its concentration in the brain parenchyma and to
study its expression in the context of the neurovascular unit
(NVU).
Concentrations of tPA
The concentration of tPA in the intravascular space is 5 µM/L
which correspond to approximately 70 pM (Nicoloso et al.,
1988). In contrast, tPA’s concentration in the extracellular
space of the brain is more difficult to quantify. However,
taking into consideration the volume of brain tissue supplied
by the middle cerebral artery (MCA) in the C57BL/6 mouse,
the release of tPA from neuronal cultures (Echeverry et al.,
2010), the area of the synaptic cleft, the concentration of tPA
in the brain tissue under ischemic conditions and following
the intravenous (IV) administration of recombinant tPA (rtPA;
Haile et al., 2012), and a 60% contraction of the interstitial
space in the ischemic brain (Hansen and Olsen, 1980), the
extracellular concentration of tPA in the brain 3 h after MCA
occlusion (MCAo) and IV treatment with either saline solution
or 0.9 mg/Kg of rtPA is not superior to 1 nM and 2–4.5 nM,
respectively. Although in all likelihood this is an overestimation
and many other factors need to be considered to improve the
accuracy of these calculations, it is clear that an experimental
design with concentrations of tPA superior to 5 nM does not
resemble tPA’s concentrations in an in vivo system, even after the
administration of rtPA. This point is of key importance for the
translatability to the clinic of results obtained in basic sciences
laboratories dedicated to the study of tPA’s effect on neuronal
survival.
tPA in the Neurovascular Unit (NVU)
The NVU is a dynamic structure assembled by ECs surrounded
by a basement membrane (BM) encased by perivascular
astrocytes (PVA). Synapses are found approximately 13 µm
away from the ECs (Zhang et al., 2005). This concept is highly
relevant because following its IV administration rtPA permeates
the brain parenchyma (Haile et al., 2012) potentially entering in
contact with the synaptic space. Althoughmicroglia and pericytes
should also be considered part of the NVU, a discussion of tPA’s
expression and function in these cells is beyond the scope of this
Review.
tPA in Endothelial Cells
Early studies in the non-human primate brain detected tPA
antigen in a small fraction of ECs of the microvasculature, 90%
of them pre-capillary arterioles and post-capillary veins (Levin
and del Zoppo, 1994). Despite the importance of these findings,
since the publication of this report more than 20 years ago, no
further attempts have been made to study with new antibodies
the expression of tPA in the brain vasculature. Nevertheless, it has
been proposed that PVA regulate the expression of tPA mRNA
in ECs (Tran et al., 1998) and that a number of stimuli including
membrane depolarization induce its release into the intravascular
space.
tPA in the Basement Membrane-Astrocyte (BM-A)
Interface
tPA is abundantly expressed in PVA and its release into the
BM-A interface has multiple effects including increase in the
permeability of the blood-brain barrier (BBB; Yepes et al.,
2003), detachment of astrocytic end-feet processes from the BM
(Polavarapu et al., 2007), and induction of an NF-κB-regulated
pro-inflammatory response (Zhang et al., 2007).
Neuronal tPA
Neurons are a major source of tPA synthesis in vivo. Studies
using in situ zymography assays (Sappino et al., 1993) have
detected tPA-catalyzed proteolysis in well-defined areas of the
adult brain, namely hippocampus, hypothalamus, thalamus,
amygdala, cerebellum and meningeal blood vessels. Intriguingly,
tPA mRNA is found in several areas of the brain that do not
display tPA-catalyzed enzymatic activity. That is the case of the
cerebral cortex and the hippocampus. In the latter structure
although tPA mRNA is widely expressed throughout all cell
layers, only the CA2 and CA3 layers and the dentate gyrus (DG)
show tPA-catalyzed proteolysis. It has been postulated that this
discrepancy between tPA catalyzed-proteolysis and tPA mRNA
expression may be due either to the localized expression of
tPA inhibitors in those areas where tPA-catalyzed proteolysis
is not observed, or to the accumulation of tPA protein at
distant places of its synthesis, or to posttranslational regulation
of tPA expression, or to the possibility that in some areas of
the brain tPA has functions that do not require the generation
of plasmin. Independently of the reason for this divergence, a
substantial body of experimental evidence indicates that tPA
is released at the neuronal growth cone (Krystosek and Seeds,
1981) and mediates neuronal migration (Seeds et al., 1999) and
neurite outgrowth and remodeling during development (Lee
et al., 2014) and in the ischemic brain (Shen et al., 2011).
Likewise, tPA promotes the development of synaptic plasticity
in in vitro and in vivo models of long-term potentiation (Qian
et al., 1993), learning (Seeds et al., 1995, 2003), stress-induced
anxiety (Pawlak et al., 2003), and visual cortex plasticity (Müller
and Griesinger, 1998). Moreover, it has also been proposed that
tPA plays a role on axonal remodeling after stroke (Liu et al.,
2012).
The Neurotoxic Effect of tPA
History
One of the first achievements in our understanding of tPA’s
role in the brain was provided by the observation that it is
induced as an immediate-early gene during seizures and long-
term potentiation, and to the identification of a functional link
between tPA and N-methyl-D-aspartate receptors (NMDAR;
Qian et al., 1993). Shortly thereafter it was found that membrane
depolarization induces the rapid release of neuronal tPA by
a mechanism that does not involve tPA mRNA or protein
synthesis but requires the influx of Ca+2 (Gualandris et al.,
1996). It was quickly recognized that the conditions associated
with the release of neuronal tPA (i.e., membrane depolarization,
increase in the intracellular concentrations of Ca+2 and NMDAR
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activation) also underlie the pathophysiological events observed
in several neurological diseases such as cerebral ischemia, head
trauma and seizures. This led to study in animal models of
experimental cerebral ischemia changes in tPA activity in the
brain tissue following MCAo. Although the interpretation of the
initial studies was confusing, soon was evident that tPA activity
increases rapidly in the ischemic tissue after MCAo (Wang et al.,
1998; Yepes et al., 2003), and that this surge disappears at later
time points when plasminogen activator inhibitor-1 (PAI-1)
antigen is detected (Hosomi et al., 2001).
These reports were rapidly followed by the seminal
observation that mice genetically deficient in tPA (tPA−/−)
in all the cellular components of the NVU have a∼41% decrease
in the volume of the ischemic lesion following MCAo (Wang
et al., 1998; Nagai et al., 1999). The impact of these findings
was contrasted by a later report from a different group of
investigators using a similar experimental design that found just
the opposite: an increase in the volume of the ischemic lesion in
tPA−/− mice (Tabrizi et al., 1999). Shortly thereafter a group of
researchers discovered neuroserpin (Osterwalder et al., 1996),
an axonally secreted serine proteinase inhibitor preferentially
expressed in neurons (Hastings et al., 1997). This finding was
followed by biochemical studies that revealed that although
neuroserpin is an efficient inhibitor of plasminogen activators
and plasmin, it has a higher affinity for tctPA (ki: 6.2 × 105
M−1 S−1), than either sctPA (ki: 8.0 × 104 M−1 S−1), or high
molecular weight uPA (ki: 2.5× 104 M−1 S−1), or low molecular
weight uPA (ki: 9.2 × 103 M−1 S−1), or plasmin (ki: 3.6 ×
102 M−1 S−1; Hastings et al., 1997). These observations led to
postulate neuroserpin as the inhibitor of tPA in the brain (Yepes
and Lawrence, 2004). With this premise in mind, later studies
with animal models of ischemic stroke revealed that either
treatment with recombinant neuroserpin (Yepes et al., 2000)
or genetic overexpression of neuroserpin (Cinelli et al., 2001)
decreases the volume of the ischemic lesion following MCAo.
Despite the discrepancies between animal studies with tPA−/−
mice, these results helped to advance the concept that tPA has
a neurotoxic effect in the ischemic brain. Since then several
research groups have reported potential mechanisms for tPA’s
harmful effects and some have attempted to develop therapeutic
strategies to antagonize it.
Clinical Relevance
The idea borne from basic sciences laboratories that tPA has a
neurotoxic effect in the ischemic brain was in striking opposition
to an almost simultaneous publication by the National Institute
of Neurological Disorders and Stroke (NINDS) of a clinical study
indicating that IV treatment with rtPA leads to complete or
nearly complete neurological recovery in a significant number
of acute ischemic stroke patients (The National Institute of
Neurological Disorders and Stroke rt-PA Stroke Study Group,
1995). Notably, although since then several clinical studies
have shown that besides improving neurological outcome rtPA
also increases the risk of intracerebral hemorrhage (Hacke
et al., 2004) and augments the permeability of the BBB
(Kidwell et al., 2008), to this date and after more than 100,000
rtPA-treated acute ischemic stroke patients, no clinical study
has shown a neurotoxic effect for rtPA. The translational
impact of this disagreement between basic and clinical research
has been heightened by the observation that following its
IV administration rtPA crosses the BBB and permeates the
ischemic tissue (Haile et al., 2012). In conclusion, while basic
researchers suggest that clinicians are treating acute ischemic
stroke patients with a neurotoxic agent, clinicians are developing
protocols to increase the number of rtPA-treated patients.
This discrepancy needs to be resolved promptly because it
has questioned the translatability into the clinic of tPA’s basic
research.
A New Look at Old Data
The translational importance of the findings described above
warrants a second examination of the published data with the
help of information that was not available when the original
results were published.
Does Genetic Deficiency of tPA Decrease the Volume
of the Ischemic Lesion after Experimental Induction
of Ischemic Stroke?
There is a growing awareness among basic science stroke
researchers that a large number of factors besides the actual
MCAo influence the quantification of the volume of the ischemic
lesion in experimental models of ischemic stroke (Sena et al.,
2010). With this in mind, it is not surprising to find that while
some studies have reported a decrease (Wang et al., 1998), others
have found an increase (Tabrizi et al., 1999) in the volume of
the ischemic lesion in tPA−/− mice following MCAo. A similar
reasoning applies to studies reporting either a deleterious (Wang
et al., 1998), or beneficial (Wu et al., 2012), or lack of effect (Klein
et al., 1999) on the volume of the ischemic lesion in animals
treated with rtPA after MCAo.
In the analysis of these reports is important to consider
that the earlier studies (Wang et al., 1998; Tabrizi et al., 1999)
were criticized by their use of mice with two different genetic
backgrounds: C57BL/6 and SV129. However, the validity of these
concerns is difficult to evaluate because although it was initially
believed that these two strains ofmice have different vulnerability
to the harmful effects of cerebral ischemia and excitotoxicity
(Carmichael, 2005), later studies using magnetic resonance
imaging (MRI) indicated that they are equally susceptible to both
forms of injury (Pham et al., 2010). Thus it is problematic to
invoke this factor to explain the opposite results observed in
these studies. It also should be kept in mind that although the
currently available tPA−/− mice lack the protease domain they
still harbor tPA’s finger, EFG and kringle domains. This fact
has gained significant relevance over the last 10 years with the
identification of several functions of tPA in the brain that do not
require the conversion of plasminogen into plasmin. Therefore,
it is difficult to assure that the finger and kringle domains do
not have an effect in the final outcome of the ischemic injury in
tPA−/− mice.
It is also relevant to consider that tPA−/− mice are deficient
on tPA in all the cellular components of the NVU. Because tPA
plays an unique and different role in ECs, PVA and neurons,
it is difficult to determine whether the final outcome observed
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in tPA−/− mice after MCAo is due to the effect of the lack of
tPA on either the permeability of the BBB, or neuronal survival,
or microglial activation. These are highly dynamic and variable
processes that need to be dissected to have a better understanding
of tPA’s role in the ischemic brain. A step to address this problem
was recently taken by a group of investigators that reported that
mice overexpressing tPA only in neurons have ∼40% decrease
in the volume of the ischemic lesion following MCAo (Wu
et al., 2012). Based on these data and our knowledge that
tPA increases the permeability of the BBB in rodents (Yepes
et al., 2003) and humans (Kidwell et al., 2008), is plausible to
postulate that the decrease in the volume of the ischemic lesion
following MCAo observed by some investigators in tPA−/−
mice may be due to abrogation tPA-induced increase in the
permeability of the BBB instead of a direct effect on neuronal
survival.
The data obtained from mice overexpressing neuroserpin
and rats treated with recombinant neuroserpin after MCAo
also deserves careful attention. Certainly, the observation of
unchanged tPA activity in animals genetically deficient in
neuroserpin (Madani et al., 2003) and the report that neuroserpin
also decreases the volume of the ischemic lesion in tPA−/− mice
(Wu et al., 2010), argue against tPA inhibition as a mechanism
whereby neuroserpin decreases the volume of the ischemic lesion
in these animals.
In summary, a new look at the available data suggests that the
determination of the volume of the ischemic lesion in tPA−/−
mice or in animals either overexpressing neuroserpin or treated
with recombinant neuroserpin after MCAo may not be sufficient
evidence to conclude that tPA has a neurotoxic effect in the
ischemic brain. Instead, data obtained from studies using animals
overexpressing tPA only in neurons suggest that tPA may have a
neuroprotective effect.
Does tPA Induce Neuronal Death?
A strategy to examine the effect of tPA on neuronal survival
without the confounding effects of tPA derived from other
cellular components of the NVU is to study cell death in
neuronal cultures incubated with rtPA. Data obtained with this
experimental design unambiguously indicate that rtPA, even
at very high concentrations, does not induce neuronal death
(Wu et al., 2013). To reconcile these observations with the
harmful effect of tPA reported by some studies with tPA−/−mice
subjected toMCAo, some investigators postulated the hypothesis
that while tPA does not directly cause neuronal death, it could
act as a mediator of the deleterious effects of other agents known
to cause neuronal death in the ischemic brain. This hypothesis
is supported by studies performed with an animal model of
neurodegeneration, namely the nervous (nr) mutant mouse,
indicating that Purkinje cell degeneration correlates with high
levels of tPA activity in the cerebellum (Li et al., 2006, 2013),
and that mice overexpressing tPA in neurons develop Purkinje
cell damage and ataxia (Cops et al., 2013). Although these
studies do not indicate that tPA directly induces neuronal death,
they suggest that under certain conditions tPA may facilitate
the neurotoxic effect of other agents. Because the excitotoxic
release of neurotransmitters underlies neuronal death in both,
the ischemic brain and neurodegenerative diseases, then the
obvious question was whether tPAmediates excitotoxin-induced
neuronal death.
Does tPA Mediate Excitotoxin-Induced Neuronal
Death?
The term excitotoxicity was coined in 1969 to describe the
harmful effect on neuronal survival caused by prolonged and
excessive activation of receptors of excitatory neurotransmitters
(Olney, 1969). Since then it has been demonstrated that
glutamate-induced excitotoxicity activates signaling pathways
that lead to neuronal death in several neurological diseases
including cerebral ischemia, seizures and head trauma (Choi,
1988). To study whether tPA mediates excitotoxin-induced
neuronal death a group of researchers quantified neuronal
demise in the hippocampus of tPA−/− mice injected into the
CA1 layer with kainic acid (KA), an excitatotoxic glutamate
analog. Using this experimental paradigm these investigators
reported extensive neuronal loss in the CA1 region of Wt but
not tPA−/− mice (Tsirka et al., 1995), and subsequent studies
led them to propose that this effect was mediated by plasmin-
induced proteolysis of laminin in the extracellular matrix (Chen
and Strickland, 1997). These studies originated the idea that
although under non-ischemic conditions tPA is pivotal for
neurophysiological processes required for normal brain function
such as neurite outgrowth (Krystosek and Seeds, 1981), learning
(Seeds et al., 2003) and memory (Baranes et al., 1998), during
cerebral ischemia it plays a completely opposite role as amediator
of excitotoxin-induced neuronal death.
In the murine hippocampus tPA protein is abundantly
expressed in the CA2 and CA3 but not the CA1 layer (Salles and
Strickland, 2002), which is known to have a high vulnerability to
KA-induced cell death (Tsirka et al., 1995). This concept acquired
special relevance when the same group of investigators found that
the injection of KA causes a transient increase in tPA activity
in some cells of the CA1 layer (Salles and Strickland, 2002).
The striking observation was that those cells that exhibited an
increase in tPA activity also survived the excitotoxic injury. Thus,
when analyzed together with a previous report by a different
research group (Kim et al., 1999) indicating that tPA protects
hippocampal cells from the harmful effects of KA, it is clear that a
casual link between tPA and excitotoxin-induced neuronal death
needs was not clear yet. Importantly, this group of investigators
also observed tPA−/− mice are resistant to KA-induced seizures
(Tsirka et al., 1995). To analyze these observations is important
to keep in mind that the onset and spreading of seizures
throughout the brain requires the development of structural and
functional changes in the synapse that allow the spread of the
abnormal electrical activity throughout neuronal circuits. Thus,
the higher resistance to pharmacologically-induced seizures in
tPA−/− mice could also be explained by the lack of tPA-
induced synaptic changes needed for the onset and spread of a
seizure.
To gain perspective for the analysis of these data is important
to keep in mind that the intrahipocampal injection of KA
also induces prolonged seizures, that although very often
remain clinically unrecognized, cause widespread hippocampal
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cell death, particularly in the CA1 layer (Meldrum, 2002).
Thus, with this experimental paradigm is difficult to analyze
whether tPA mediates KA- or seizures-induced neuronal death.
To answer this question, a research group used two different
experimental approaches. In the first, they studied the clinical
and electrophysiological spread of seizures throughout the limbic
system in tPA−/− and Wt mice injected with KA into the
amygdala (Yepes et al., 2002). The fact that KA was not
injected directly into the hippocampus allowed these researchers
to dissect KA- from seizures-induced hippocampal neuronal
death. These experiments indicated that genetic deficiency
of tPA is associated with slower progression of KA-induced
seizure activity throughout the limbic system and a decrease
in seizures-induced hippocampal cell death. In the second
approach, they used an animal model in which transient
occlusion of both common carotid arteries causes hippocampal
cell death (Echeverry et al., 2010). With this paradigm these
investigators were able to evaluate the effect on neuronal survival
of endogenous glutamate released from hippocampal neurons
in response to an ischemic insult. These studies showed that,
as it was demonstrated years before in animals treated with
KA (Salles and Strickland, 2002), hippocampal ischemia also
causes an increase in tPA activity in the hippocampal CA1 layer.
Remarkably, these investigators found that, as was also reported
by the earlier studies with KA-injected mice, CA1 neurons that
exhibit an increase in tPA activity also survive the ischemic
injury. In agreement with these observations, it was found that
hippocampal neurons of tPA−/− mice are more vulnerable to
the ischemic injury than those of their Wt littermate controls.
Together, these data suggested a neuroprotective role of tPA
against ischemia-induced excitotoxic neuronal death.
To study the effect of tPA on excitotoxin-induced neuronal
death without the confounding effect of seizures, a group of
researchers injected NMDA, another glutamate analog, into the
striatum followed by IV treatment with rtPA. The advantage
of this model is that the injection of NMDA into the striatum
causes neuronal death but not seizures. Using this approach,
these investigators (Reddrop et al., 2005) found that 10mg/Kg/IV
of rtPA increases the volume of the necrotic lesion caused by the
injection of NMDA. Moreover, the same group of investigators
measured the volume of the necrotic area induced by the direct
intrastriatal injection of NMDA alone or in the presence of 3 µg
of either rtPA or desmoteplase, the plasminogen activator from
the vampire bat Demodus rotundus (Liberatore et al., 2003), and
found that tPA but not desmoteplase increased NMDA-induced
neuronal death.
Together, these studies were interpreted as another
demonstration that tPA enhances excitotoxin-induced neuronal
death. Intriguingly, the dose of tPA used for the intracerebral
injections was unusually large (3 µg) and at this moment
is difficult to elucidate why desmoteplase did not potentiate
NMDA’s effect. More importantly, the dose of IV rtPA
administered by these researchers is widely used by many
investigators because it is believed that rodent plasminogen is
10-fold more resistant than human plasminogen to the catalytic
action of rtPA. However, this concept has been challenged, and
later studies with animal models of embolic stroke indicate that
the dose of rtPA used to treat acute ischemic stroke patients
(0.9 mg/Kg/IV) is also effective in rodents (Haelewyn et al.,
2010). This has proved to be a very important fact because a
different group of investigators using the same experimental
paradigm demonstrated that treatment with 0.9 mg/Kg/IV of
rtPA has just the opposite effect: a decrease in the volume of the
necrotic lesion induced by the intrastraiatal injection of NMDA
(Wu et al., 2013). In line with these observations, the damage
induced by the intrastrial injection of NMDA was significantly
attenuated in mice overexpressing tPA in neurons.
These studies underscored the need to investigate the effect
of different doses of tPA on excitotoxin-induced neuronal
death. With this concept in mind, this group of investigators
quantified neuronal survival in Wt cerebral cortical neurons
incubated with NMDA in the presence of 0–500 nM of either
proteolytically active tPA or a mutant of tPA with an alanine
for serine substitution at the active site Ser481 that renders it
unable to catalyze the conversion of plasminogen into plasmin
(proteolytically inactive tPA; Wu et al., 2013). These experiments
indicated that tPA causes a modest increase in NMDA-induced
neuronal death only at doses greater than 100 nMwhich, as it was
discussed above, result in a concentration of tPA not found in an
in vivo system, even after treatment with rtPA. In sharp contrast
with these findings, the most important observation was that
at concentrations found in the ischemic brain, tPA attenuates
NMDA-induced neuronal death by a mechanism that does not
entail plasmin generation but requires a co-receptor function by
a member of the low-density lipoprotein receptor (LDLR) family,
most likely LRP1.
What is the Nature of tPA’s Interaction with NMDA
Receptors (NMDARs)?
Despite abundant experimental evidence indicating that
NMDARs mediate excitotoxin-induced neuronal death, clinical
studies with ischemic stroke patients treated with NMDAR
blockers were disappointing, showing either lack of or, in
some cases, harmful effects that precluded their use (Davis
et al., 2000). To understand this divergence between basic and
clinical research is important to take into account that NMDARs
are assembled by obligatory NR1 sub-units that interact with
NR2A—D sub-units, generating a specific sub-unit composition
that determines the function of the receptor. Hence, while
NR2A-containing NMDARs are located in the synapse and their
activation has been coupled to neuronal survival (Liu et al.,
2007), most of the NR2B- and NR2D-containing NMDARs are
extrasynaptic and linked to the activation of cell-death pathways
(Hardingham and Bading, 2010).
Although a functional association between tPA and NMDARs
has been identified by several researchers, it was not until 2001
when a group of investigators reported that at ∼280 nM of tPA
enhances NMDA-induced neuronal death via a plasminogen-
independent proteolytic cleavage of the NR1 sub-unit of the
NMDAR that leads to increase in Ca+2 permeability (Nicole
et al., 2001). These striking results led to postulate the NR1
sub-unit as a therapeutic target to antagonize the purported
deleterious effect of tPA on excitotoxin-induced neuronal
death. Unfortunately, since then a number of investigators
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have been unable to replicate these findings (Matys and
Strickland, 2003; Samson et al., 2008; Wu et al., 2013). The
controversy has been further enhanced by an elegant study
indicating that the interaction between tPA and NMDARs
does not involve the cleavage of the NR1 sub-unit but instead
that it requires a co-receptor function of a member of the
LDLR family (Samson et al., 2008). Additionally, several
investigators have convincingly demonstrated that NMDARs
are a discrete proteolytic target for plasmin but not for tPA
(Matys and Strickland, 2003; Yuan et al., 2009; Echeverry et al.,
2010).
A further advance in our understanding of tPA’s interaction
with the NMDAR was provided by subsequent studies indicating
that at concentrations likely to be found in an in vivo system
tPA protects neurons against excitotoxin-induced cell death (Wu
et al., 2013). Furthermore, the same group demonstrated that
1–10 nM of tPA induces phosphorylation but not cleavage
of the NR2A sub-unit of the NMDAR at Y1325, and that
this event leads to ERK 1/2-mediated activation of the cAMP
response element binding protein (CREB) and induction of
the neuroprotective effect of the CREB-regulated activating
transcription factor 3 (Atf3). In line with these observations
Atf3’s down-regulation abrogated tPA’s protective effect against
excitotoxin-induced neuronal death. In this study tPA induced
phosphorylation, but not cleavage, of extrasynaptic NR2B sub-
units at Tyr1472 only at concentrations greater than 200 nM.
These findings were also observed in in vivo studies with
mice overexpressing neuronal tPA. This work also indicated
that the non-proteolytic interaction between tPA and NMDARs
requires the co-receptor function of a member of the LDLR
family. An important point brought to light by these studies
is the existence of a dose-dependent effect of tPA on NMDAR
phosphorylation, where a protective NR2A-mediated response
is activated by concentrations of tPA expected in an in vivo
system, while a harmful NR2B-mediated neurotoxic pathway is
triggered by concentrations of tPA unlikely to be found in the
synapse.
In summary, a link between tPA and excitotoxin-induced
neuronal death is not clear yet. Furthermore, although the
functional association between tPA and NMDARs has been
substantiated by a large number of studies, the mechanism
underlying this interaction and its impact on cell survival remain
contentious. The resolution of this controversy if of the utmost
importance not only for the clinical implications of these findings
but also for their obvious repercussions on the conceptual
advancement of the field of tPA research.
The Emergence of a New Paradigm: tPA is
a Neuroprotectant in the Central Nervous
System (CNS)
Several lines of evidence suggest that tPA could instead be
a neuroprotectant in the central nervous system (CNS). This
concept, that was already suggested by earlier studies indicating
that tPA protects neurons from excitotoxin-, seizures- (Kim
et al., 1999) and serum deprivation-induced cell death (Liot
et al., 2006), has been further advanced by more recent work
with lower doses of rtPA and mice overexpressing tPA only in
neurons.
tPA Promotes Survival in Neurons Exposed to
Oxygen and Glucose Deprivation (OGD)
To study tPA’s effect on neuronal survival we designed an in vitro
model of ischemic stroke in which we quantified cell survival in
Wt cerebral cortical neurons treated with 5 nM of rtPA between
5 min and 6 h after exposure to 55 min of oxygen and glucose
deprivation (OGD). Our data indicated that treatment with
rtPA protects cerebral cortical neurons from OGD-induced cell
death. This effect is independent of tPA’s proteolytic activity and
although is abrogated by NMDAR and LRP1 antagonism with
MK-801 and the receptor-associated protein (RAP), respectively
(Echeverry et al., 2010), it remains unchanged by inhibition
of the tyrosine kinase receptor B (TrkB), the cognate receptor
of brain-derived neurotrophic factor (BDNF). Intriguingly, the
detection of a maximal neuroprotective effect in cells treated
within the first 3 h after OGD, and still present albeit with
less intensity in cells treated 6 h after the hypoxic insult,
has a notable resemblance with the probability of neurological
recovery observed in acute ischemic stroke patients treated with
rtPA (Hacke et al., 2004).
The obvious lack of a clot in our in vitro system indicated
that a mechanism other than thrombolysis mediates tPA’s
neuroprotective effect. To better characterize these results Wt
mice underwent transient MCAo followed immediately after
reperfusion by treatment with 0.9 mg/Kg/IV of rtPA or a
comparable volume of saline solution, and quantification of
the volume of the ischemic lesion 24 h later. We found that
treatment with rtPA decreases the volume of the ischemic lesion.
However, because MCAo was performed with a nylon suture
instead of a clot, it was evident that, as suggested by our in
vitro studies, the mechanism of this effect is independent of
tPA’s ability to generate plasmin. This was further confirmed
by our finding that treatment with rtPA also decreases the
volume of the ischemic lesion in mice genetically deficient on
plasminogen (Plg−/−). These data indicated that tPA has a
neuroprotective effect in the ischemic brain that is not mediated
by the generation of plasmin and instead requires the co-
receptor function of the NMDAR and a member of the LDLR
family.
tPA-induced Neuroprotection: A Proteomics
Approach
These results implied the activation of a neuroprotective cell
signaling pathway by tPA. To test this hypothesis, we used liquid
chromatography coupled to tandem mass spectrometry (LC-
MS/MS) and quantitative analysis to identify protein changes
in Wt cerebral cortical neurons incubated with 5 nm of
either proteolytically active or inactive rtPA. We found that
compared to vehicle (control)-treated neurons, treatment with
rtPA causes a >50% change in abundance in 589 unique
neuronal proteins, by a mechanism that does not involve plasmin
generation. Further studies with the Ingenuity Pathway Analysis
tool showed that most of these proteins belong either to the
oxidative phosphorylation (72 out of 160 proteins) or the
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FIGURE 1 | Proposed mechanism for tPA-induced neuroprotection.
Tissue-type plasminogen activator (tPA) either released from the presynaptic
terminal (red circles) or given as a treatment (rtPA; red circles with a black
margin) interact with a co-receptor formed by the low density lipoprotein
receptor-related protein (LRP1; orange line) and the NMDA receptor (yellow
squares) on the surface of the dendritic spine (post-synaptic compartment),
leading to mTOR activation and mTOR-induced synthesis of the glucose
transporter GLU3 (orange arrows) with the resultant increase in the uptake of
glucose (green triangles).
mammalian target of rapamycin pathways (mTOR; 53 of 201
proteins) pathways. In agreement with these results,Western blot
analysis indicated that either treatment of Wt cerebral cortical
neurons with rtPA, or the IV administration of rtPA after the
onset of cerebral ischemia, induces mTOR activation. More
importantly, mTOR inhibition with rapamycin abrogated tPA-
induced neuroprotection in vitro in cerebral cortical neurons
exposed to OGD conditions and in vivo in Wt mice subjected
to MCAo (Wu et al., 2012). Together, these data indicated that
tPA’s neuroprotective effect is mediated by its ability to activate
the mTOR pathway.
tPA Promotes the Detection and Adaptation to
Metabolic Stress
Hypoxia-inducible factor-1α (HIF-1α) is a trascription factor
that plays a central role in hypoxia sensing and adaptation.
HIF-1α expression is regulated by mTOR, and its accumulation
has a neuroprotective effect in the ischemic brain (Shi, 2009).
We found that either incubation with 5 nM of rtPA or
the IV administration of 0.9 mg/Kg of rtPA induces HIF-
1α accumulation in cultured neurons and in the ischemic
brain, respectively. Furthermore, shRNA-induced HIF-1α down-
regulation abrogated the neuroprotective effect of rtPA in
neurons exposed to OGD conditions (Wu et al., 2012). More
importantly, we found that tPA-induced mTOR-mediated HIF-
1α accumulation leads to the recruitment of the neuronal
transporter of glucose GLU3 to the neuronal plasma membrane.
In line with these observations, tPA induced the uptake of glucose
both in Wt cerebral cortical neurons in vitro and the ischemic
brain in vivo.
Proposed Mechanistic Model for
tPA-Induced Neuroprotection
Based on these data and other results not discussed here
(An et al., 2014), we propose a model whereby tPA either
released in the synaptic cleft following the onset of cerebral
ischemia or intravenously administered interacts with LRP1,
leading to NMDAR-mediatedmTOR activation, mTOR-induced
HIF-1α accumulation, HIF-1α-induced recruitment of the
neuronal transporter of glucose GLUT3 to the neuronal plasma
membrane, and GLUT3-mediated uptake of glucose by neurons
in the ischemic brain (Figure 1). In summary, here we propose
a mechanistic model whereby tPA is a neuroprotectant in the
ischemic brain by its ability to promote the detection and
adaptation to the metabolic stress triggered by the lack of oxygen
and glucose.
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